High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Drug Store News11h
CVS Caremark taps Ed DeVaney as president of PBM business
DeVaney was named interim president of Caremark's PBM business in December 2024. CVS Health has named Ed DeVaney president of the company’s Caremark pharmacy benefit management business. Named interim ...
Is It Too Late to Buy CVS Health Stock for the High-Yield Dividend?
Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...
Fierce Healthcare23h
CVS taps Ed DeVaney to lead its Caremark PBM
CVS Health has named Ed DeVaney as president of its pharmacy benefit manager, CVS Caremark. | DeVaney has served as interim ...